Royal Bank of Canada
TEVA icon

Royal Bank of Canada’s Teva Pharmaceuticals TEVA Stock Holding History

Royal Bank of Canada’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-245,300
Closed -$1.98M – 7712
2022
Q3 		$1.98M Sell
245,300
-293,900
-55% -$2.6M ﹤0.01% 2862
2022
Q2 		$4.05M Buy
+539,200
New +$4.7M ﹤0.01% 2275
2021
Q1 		– Sell
-104,000
Closed -$1M – 7691
2020
Q4 		$1M Buy
+104,000
New +$996K ﹤0.01% 3485
2020
Q2 		– Sell
-45,300
Closed -$407K – 6900
2020
Q1 		$407K Sell
45,300
-440,200
-91% -$4.51M ﹤0.01% 3792
2019
Q4 		$4.76M Hold
485,500
– – ﹤0.01% 2183
2019
Q3 		$3.34M Buy
485,500
+484,800
+69,257% +$3.71M ﹤0.01% 2357
2019
Q2 		$7K Sell
700
-2,100
-75% -$25.3K ﹤0.01% 6176
2019
Q1 		$44K Sell
2,800
-13,600
-83% -$240K ﹤0.01% 5234
2018
Q4 		$253K Buy
16,400
+300
+2% +$6.15K ﹤0.01% 4205
2018
Q3 		$347K Hold
16,100
– – ﹤0.01% 4136
2018
Q2 		$392K Hold
16,100
– – ﹤0.01% 3972
2018
Q1 		$275K Sell
16,100
-210,000
-93% -$4.1M ﹤0.01% 4120
2017
Q4 		$4.29M Buy
226,100
+92,100
+69% +$1.39M ﹤0.01% 2169
2017
Q3 		$2.36M Buy
134,000
+80,300
+150% +$1.81M ﹤0.01% 2532
2017
Q2 		$1.78M Buy
53,700
+38,900
+263% +$1.2M ﹤0.01% 2679
2017
Q1 		$475K Sell
14,800
-390,200
-96% -$13.3M ﹤0.01% 3683
2016
Q4 		$14.7M Buy
405,000
+316,900
+360% +$12.7M 0.01% 1253
2016
Q3 		$4.05M Sell
88,100
-256,100
-74% -$13.4M ﹤0.01% 2054
2016
Q2 		$17.3M Buy
344,200
+260,600
+312% +$13.9M 0.01% 1055
2016
Q1 		$4.47M Sell
83,600
-228,800
-73% -$13.4M ﹤0.01% 1891
2015
Q4 		$20.5M Buy
312,400
+205,300
+192% +$12.7M 0.01% 955
2015
Q3 		$6.05M Buy
107,100
+37,100
+53% +$2.41M ﹤0.01% 1467
2015
Q2 		$4.14M Sell
70,000
-20,000
-22% -$1.23M ﹤0.01% 1740
2015
Q1 		$5.61M Sell
90,000
-358,300
-80% -$20.8M ﹤0.01% 1530
2014
Q4 		$25.8M Buy
448,300
+255,700
+133% +$14.2M 0.02% 711
2014
Q3 		$10.4M Buy
192,600
+142,600
+285% +$7.55M 0.01% 1197
2014
Q2 		$2.62M Hold
50,000
– – ﹤0.01% 2095
2014
Q1 		$2.64M Buy
+50,000
New +$2.31M ﹤0.01% 2049

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's TEVA Position: Q1 2026 in Review

Royal Bank of Canada increased its Teva Pharmaceuticals (TEVA) stake by 11% in Q1 2026, buying an estimated $3.12M and bringing the position to 963,824 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1207.

Royal Bank of Canada first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $130M in Q2 2013. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Royal Bank of Canada held 963,824 shares of Teva Pharmaceuticals worth $29M as of Q1 2026.
  • Royal Bank of Canada bought 96,938 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.12M.
  • Teva Pharmaceuticals made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1207 holding.
  • Royal Bank of Canada first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Teva Pharmaceuticals position peaked at $130M in Q2 2013.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.